Mission – To serve life scientists to achieve their mission, faster
Vision – To be the most influential life company for life scientists worldwide
Our strategy is designed to generate sustainable sales and earnings growth and improved returns to shareholders. We have five strategic priorities:
- sustain our antibody and digital marketing leadership;
- expand in related growth markets;
- Invest in operating capabilities for 2x 2016 scale by 2023;
- sustain attractive economics; and
- supplement organic growth – partnerships and acquisitions
Abcam has a strong track record of executing on these priorities and has transitioned from being a small high growth company to being a significant player in our core markets, with future expansion potential through targeted investment. Abcam is the market leader in primary antibodies for use in research. It is our goal to continue to grow the Company and create value for all of our stakeholders. We have always delivered on our promises and we will continue to focus on understanding our customers, delivering high quality products, and being the innovation partner of choice for the researchers we serve globally.
For further detail on our strategy and how we are delivering against our priorities, please see our 2018 Annual Report, which can be downloaded here.